{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:58:14Z","timestamp":1792835894768,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cllc.2023.02.010","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T07:02:25Z","timestamp":1679382145000},"page":"415-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-4165","authenticated-orcid":false,"given":"Makoto","family":"Nishio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary T.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Visseren-Grul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cllc.2023.02.010_bib0001","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijms.34739","article-title":"Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications","volume":"16","author":"Zito Marino","year":"2019","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.cllc.2023.02.010_bib0002","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J Thorac Dis"},{"issue":"5","key":"10.1016\/j.cllc.2023.02.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000919","article-title":"Understanding EGFR heterogeneity in lung cancer","volume":"5","author":"Passaro","year":"2020","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.cllc.2023.02.010_bib0004","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"British J Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2023.02.010_bib0005","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2023.02.010_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: a double role in lung cancer cell survival?","volume":"4","author":"Suda","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.02.010_bib0007","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.3389\/fonc.2020.610923","article-title":"Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-Mutant non-small cell lung cancer: a review","volume":"10","author":"Guo","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2023.02.010_bib0008","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.2147\/CMAR.S201513","article-title":"Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC","volume":"11","author":"Hou","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.cllc.2023.02.010_bib0009","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","article-title":"Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis","volume":"20","author":"Qin","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2023.02.010_bib0010","article-title":"TP53 mutations in nonsmall cell lung cancer","volume":"2011","author":"Mogi","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"12","key":"10.1016\/j.cllc.2023.02.010_bib0011","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1177\/1947601911407324","article-title":"The genomics of lung adenocarcinoma: opportunities for targeted therapies","volume":"1","author":"Greulich","year":"2010","journal-title":"Genes Cancer"},{"issue":"9","key":"10.1016\/j.cllc.2023.02.010_bib0012","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.cllc.2023.02.010_bib0013","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00109-007-0221-2","article-title":"Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome","volume":"85","author":"Teodoro","year":"2007","journal-title":"J Mol Med (Berl)"},{"issue":"7","key":"10.1016\/j.cllc.2023.02.010_bib0014","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-14-2305","article-title":"VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy","volume":"75","author":"Schwaederl\u00e9","year":"2015","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.cllc.2023.02.010_bib0015","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-11-2348","article-title":"p53 inhibits angiogenesis by inducing the production of Arresten","volume":"72","author":"Assadian","year":"2012","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.cllc.2023.02.010_bib0016","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/jcm9041047","article-title":"Concomitant tp53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs","volume":"9","author":"Canale","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.cllc.2023.02.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2020.11.001","article-title":"Predictive and prognostic potential of TP53 in patients with advanced non-small-cell lung cancer treated with EGFR-TKI: analysis of a phase III randomized clinical trial (CTONG 0901)","volume":"22","author":"Li","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"17","key":"10.1016\/j.cllc.2023.02.010_bib0018","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer","volume":"20","author":"Molina-Vila","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.cllc.2023.02.010_bib0019","doi-asserted-by":"crossref","first-page":"44194","DOI":"10.18632\/oncotarget.9925","article-title":"Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma","volume":"7","author":"Lapke","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.cllc.2023.02.010_bib0020","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.21.00192","article-title":"Drugging the master regulator TP53 in cancer: mission possible?","volume":"39","author":"Blandino","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.cllc.2023.02.010_bib0021","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa073770","article-title":"TP53 mutations and survival in squamous-cell carcinoma of the head and neck","volume":"357","author":"Poeta","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.02.010_bib0022","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2017.01.011","article-title":"Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes","volume":"106","author":"VanderLaan","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.02.010_bib0023","article-title":"Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non-small-cell lung cancer","volume":"2018","author":"Aggarwal","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2023.02.010_bib0024","doi-asserted-by":"crossref","first-page":"v149","DOI":"10.1093\/annonc\/mdz243.015","article-title":"405P - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer","volume":"30","author":"Chen","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2023.02.010_bib0025","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","article-title":"TP53 alterations correlate with response to VEGF\/VEGFR inhibitors: implications for targeted therapeutics","volume":"15","author":"Wheler","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.cllc.2023.02.010_bib0026","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/annonc\/mdv598","article-title":"TP53 mutational status is predictive of pazopanib response in advanced sarcomas","volume":"27","author":"Koehler","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2023.02.010_bib0027","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/cancers12082049","article-title":"TP53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with ramucirumab\/paclitaxel or standard chemotherapy","volume":"12","author":"Graziano","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.cllc.2023.02.010_bib0028","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","article-title":"Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2023.02.010_bib0029","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/bjc.2012.461","article-title":"Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway","volume":"107","author":"Joshi","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2023.02.010_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/15384047.2019.1665956","article-title":"Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues","volume":"21","author":"Li","year":"2020","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"10.1016\/j.cllc.2023.02.010_bib0031","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/cas.14801","article-title":"VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers","volume":"112","author":"Watanabe","year":"2021","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.cllc.2023.02.010_bib0032","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-vegf pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2023.02.010_bib0033","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2023.02.010_bib0034","doi-asserted-by":"crossref","first-page":"9564","DOI":"10.1200\/JCO.2020.38.15_suppl.9564","article-title":"RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC)","volume":"38","author":"Nishio","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2023.02.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer cell"},{"issue":"12","key":"10.1016\/j.cllc.2023.02.010_bib0036","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2023.02.010_bib0037","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"National Comprehensive Cancer Network","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 4","key":"10.1016\/j.cllc.2023.02.010_bib0038","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2023.02.010_bib0039","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","article-title":"The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV","volume":"24","author":"Akamatsu","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2023.02.010_bib0040","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-05-1029","article-title":"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer","volume":"12","author":"Olivier","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cllc.2023.02.010_bib0041","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2021.04.010","article-title":"A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): results from the ETOP BOOSTER trial","volume":"32","author":"Soo","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.02.010_bib0042","doi-asserted-by":"crossref","first-page":"S950","DOI":"10.1016\/j.annonc.2021.08.1812","article-title":"1207O Bevacizumab\u00a0+\u00a0erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: final analysis of the multicenter, randomized, phase III BEVERLY trial","volume":"32","author":"Piccirillo","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2023.02.010_bib0043","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"10.1016\/j.cllc.2023.02.010_bib0044","doi-asserted-by":"crossref","first-page":"S614","DOI":"10.1016\/j.jtho.2021.01.1119","article-title":"P76.62 RAMOSE: an open-label randomized phase II study of Osimertinib with or without ramucirumab in TKI-Na\u00efve EGFR-mutant metastatic NSCLC","volume":"16","author":"Saltos","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.cllc.2023.02.010_bib0045","article-title":"A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833","volume":"37","author":"Nakahara","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2023.02.010_bib0046","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.cllc.2021.10.007","article-title":"Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non\u2013small cell lung cancer positive for the L858R mutation of EGFR: REVOL858R (WJOG14420L)","volume":"23","author":"Haratake","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2023.02.010_bib0047","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2023.02.010_bib0048","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.cllc.2023.02.010_bib0049","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.02.010_bib0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.semcancer.2020.07.005","article-title":"Targeting p53 for the treatment of cancer","volume":"79","author":"Duffy","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cllc.2023.02.010_bib0051","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1016\/j.annonc.2021.08.1038","article-title":"516MO Phase I\/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:41Z","timestamp":1761506081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1525730423000463"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.02.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}